Navigation Links
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Date:6/26/2009

DEERFIELD, Ill., June 26, and OSAKA, Japan, June 27, 2009 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary received on June 26 (U.S. time) a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA and Takeda have been in discussions about conducting an additional cardiovascular study for alogliptin.

As previously announced on March 6, 2009, the FDA informed Takeda that, although the alogliptin NDA was filed prior to the release of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that Guidance. The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA Guidance.

"Takeda will continue to promote key initiatives in order to realize sustained growth from a medium- to long-term perspective," said Takeda President & CEO, Yasuchika Hasegawa.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate Web site, www.takeda.com.

About Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Applied BioMath ... modeling to drug research and development, today announced ... 2017.  QSP Day 2017 is a day full ... quantitative systems pharmacology (QSP) community. The focus is ... is de-risking and accelerating drug research and development. ...
(Date:3/22/2017)... National Medical Products announced its J-Tip ... Technology contract from Vizient, Inc ., the ... The contract was based on a recommendation of ... this category who serve on one of Vizient,s ... technologies that demonstrate an ability to enhance clinical ...
(Date:3/22/2017)...   Upsher-Smith Laboratories, Inc . (Upsher-Smith) today announced the ... mg and 75 mg, the generic equivalent to Mallinckrodt Pharmaceuticals, ... The clomipramine hydrochloride capsules market had U.S. sales of approximately ... to IMS Health. ... "Upsher-Smith has long been recognized within the pharmaceutical ...
Breaking Medicine Technology:
(Date:3/22/2017)... , ... March 22, 2017 , ... ... assistance and financial consultations to families and business owners in the greater Hampton ... the local American Cancer Society Relay For Life event. , Each year, hundreds ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... financial planning services to regional families and business owners, is joining the Teen ... young people in the area. , A growing number of Oklahoma teens and ...
(Date:3/22/2017)... ... ... Chris Humphrey Insurance Agency, a North Carolina firm offering asset protection services and ... initiating a charity event to raise support for five year old Dillyn, a young ... Friday evening in September 2014. At the time, Dillyn was only four years old, ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... The ... debt ceiling and prevent a default on the federal debt — including the debt ... is a growing concern, ” said TSCL in a letter to House and Senate ...
(Date:3/22/2017)... ... 2017 , ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar ... in the U.S. and focused on a new protocol for treating pain. Dr. Shoshany ... New York, and furthermore the first seminar in the country was hosted at his ...
Breaking Medicine News(10 mins):